[go: up one dir, main page]

MX2023005140A - Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma. - Google Patents

Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.

Info

Publication number
MX2023005140A
MX2023005140A MX2023005140A MX2023005140A MX2023005140A MX 2023005140 A MX2023005140 A MX 2023005140A MX 2023005140 A MX2023005140 A MX 2023005140A MX 2023005140 A MX2023005140 A MX 2023005140A MX 2023005140 A MX2023005140 A MX 2023005140A
Authority
MX
Mexico
Prior art keywords
sub
drug
agonists
formulation
methods
Prior art date
Application number
MX2023005140A
Other languages
English (en)
Inventor
Brooks Boyd
FARR Stephen J
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023005140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of MX2023005140A publication Critical patent/MX2023005140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen combinaciones de fármacos y su uso. Un primer fármaco se administra en combinación con un segundo fármaco. El primer fármaco, tal como fenfluramina, se caracteriza por la formación de un metabolito que incluye agonistas de 5-HT2B como la norfenfluramina con efectos secundarios adversos conocidos. El segundo fármaco está en forma de un inhibidor de CYP, tal como el cannabidiol, el cual modula la formación de metabolitos reduciéndolos, lo que hace que el primer fármaco sea más seguro.
MX2023005140A 2016-08-24 2019-02-13 Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma. MX2023005140A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US201762515383P 2017-06-05 2017-06-05

Publications (1)

Publication Number Publication Date
MX2023005140A true MX2023005140A (es) 2023-05-26

Family

ID=59955585

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001799A MX2019001799A (es) 2016-08-24 2017-08-02 Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
MX2023005140A MX2023005140A (es) 2016-08-24 2019-02-13 Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001799A MX2019001799A (es) 2016-08-24 2017-08-02 Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.

Country Status (15)

Country Link
US (6) US20180055789A1 (es)
EP (2) EP3518975B1 (es)
JP (3) JP2019526544A (es)
KR (3) KR20190040237A (es)
CN (2) CN120241681A (es)
AU (3) AU2017315273B2 (es)
CA (1) CA3032996C (es)
ES (1) ES3029536T3 (es)
IL (2) IL290727B2 (es)
MX (2) MX2019001799A (es)
RU (2) RU2021106383A (es)
SG (1) SG11201900975XA (es)
TW (3) TWI776407B (es)
WO (1) WO2018037306A1 (es)
ZA (1) ZA201900766B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
HUE071191T2 (hu) 2015-12-22 2025-08-28 Zogenix International Ltd Fenfluraminkészítmények és eljárások elõállításukra
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2019240561A1 (ko) 2018-06-15 2019-12-19 주식회사 엘지화학 장식 부재
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
EP3887481A4 (en) * 2018-11-30 2022-08-03 Zogenix International Limited METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
KR20220101610A (ko) 2019-09-17 2022-07-19 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 간질 환자를 치료하는 방법
CN115003289B (zh) * 2019-11-21 2025-01-10 新凯治疗有限公司 大麻二酚和/或考比司他联合药物疗法
WO2021222009A1 (en) * 2020-04-30 2021-11-04 Taho Pharmaceuticals Ltd. Clobazam transdermal delivery system and uses thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230165810A1 (en) * 2021-12-01 2023-06-01 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025174742A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Concomitant administration of miricorilant with cyp2c19 inhibitors
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (es) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) * 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) * 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
ATE187436T1 (de) 1993-08-06 1999-12-15 Upjohn Co 2-aminoindane als selektive dopamin-d3-liganden
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
EP0762877B1 (en) 1994-06-03 2001-03-21 THEJMDE Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
IL143733A0 (en) 1998-12-23 2002-04-21 Orphan Medical Inc Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US20020032581A1 (en) 2000-07-17 2002-03-14 Reitberg Donald P. Single-patient drug trials used with accumulated database: risk of habituation
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EP1399015B1 (en) 2001-06-22 2010-01-27 Université Catholique de Louvain Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
BR0211794A (pt) 2001-07-31 2004-11-03 Wyeth Corp Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
CN101374525A (zh) 2004-09-23 2009-02-25 莫茨药物股份两合公司 美金刚治疗儿童行为障碍
US20090216132A1 (en) 2005-03-21 2009-08-27 Tuvi Orbach System for Continuous Blood Pressure Monitoring
US20060270611A1 (en) 2005-05-25 2006-11-30 Dries Willy M A Pediatric formulation of topiramate
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP1937255A4 (en) 2005-09-14 2013-06-26 Univ Witwatersrand Jhb PHARMACEUTICAL COMPOSITION
CN101583311B (zh) 2005-09-19 2012-06-27 比奥莱特有限公司 用于检测癫痫事件的装置和方法
CA2630604C (en) 2005-11-29 2016-01-19 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1971394A4 (en) 2005-12-28 2009-04-01 Neurovista Corp METHOD AND SYSTEMS FOR PROPOSING A TREATMENT FOR A PATIENT TO CHECK EPILEPSIA AND OTHER NEUROLOGICAL DISEASES
JP2009525977A (ja) 2006-02-06 2009-07-16 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
EP2061471A4 (en) 2006-08-31 2012-02-01 Univ Alberta PROCESS FOR INHIBITING RESTRICTED DEPRESSION WITH POSITIVE ALLOSTER AMPA RECEPTOR MODULATORS
BRPI0718509A2 (pt) * 2006-09-22 2015-09-29 Novartis Ag compostos orgânicos heterocíclicos
US20080183498A1 (en) 2007-01-31 2008-07-31 Quintiles Transnational Corp., Inc. Methods and systems for site startup
US20100130607A1 (en) 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
WO2008104524A1 (en) 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
CA2735857C (en) 2008-09-05 2019-05-28 Petra Bloms-Funke Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
EA018401B1 (ru) 2008-10-09 2013-07-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Жидкий фармацевтический состав, содержащий парацетамол
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
WO2010104841A2 (en) 2009-03-09 2010-09-16 Celgene Corporation Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
JP5711724B2 (ja) 2009-04-15 2015-05-07 リサーチ・トライアングル・インスティチュート モノアミン再取り込み阻害剤
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
UY33173A (es) 2010-01-08 2011-07-29 Eurand Inc
ES2640955T3 (es) 2010-03-09 2017-11-07 Perceptimed, Inc. Verificación y dispensación de medicación
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
CA2805760A1 (en) * 2010-07-30 2012-02-02 Merck Sharp & Dohme Corp. Inhibition of cyp3a drug metabolism
US20130315994A1 (en) 2010-09-01 2013-11-28 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
CN103189055A (zh) 2010-10-26 2013-07-03 雅来制药有限责任公司 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) * 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
DE102012213040B4 (de) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder für physikalisch nicht klonbare Funktionen mittels Schwellendekodierung und entsprechendes Verfahren
US20150291597A1 (en) 2012-11-15 2015-10-15 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
RS60679B1 (sr) 2013-07-25 2020-09-30 Neuren Pharmaceuticals Ltd Neurozaštitna biciklična jedinjenja i postupci za njihovu upotrebu u lečenju poremećaja iz spektra autizma i neurorazvojnih poremećaja
EP3035926B1 (en) 2013-08-19 2020-07-29 The Regents of The University of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015077057A1 (en) 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
JP6147676B2 (ja) * 2014-01-07 2017-06-14 東芝テック株式会社 情報処理装置、店舗システム及びプログラム
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
CN106461677B (zh) 2014-04-22 2018-09-11 国立大学法人东北大学 肺高血压病的检查方法
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
AU2015326472B2 (en) 2014-09-29 2020-05-28 Zogenix International Limited Control system for control of distribution of medication
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2016127170A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
LT3261640T (lt) 2015-02-25 2022-07-11 The Regents Of The University Of California 5ht agonistai epilepsijos sutrikimų gydymui
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) * 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
MX389016B (es) 2015-06-17 2025-03-20 Univ Columbia Terapia con desoxinucleósidos para enfermedades generadas por grupos de nucleótidos desequilibrados, inclusive síndromes de agotamiento del adn mitocondrial.
RU2734506C2 (ru) 2015-06-30 2020-10-19 Нейрад Лтд. Новые модулирующие регуляцию дыхания соединения и способы их получения и применения
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
KR102481631B1 (ko) 2015-08-24 2022-12-27 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
HUE071191T2 (hu) 2015-12-22 2025-08-28 Zogenix International Ltd Fenfluraminkészítmények és eljárások elõállításukra
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CN108699312B (zh) 2016-01-14 2021-04-20 Ａｇｃ株式会社 含氟树脂溶液、含氟树脂溶液的制造方法、涂料组合物及涂装物品
JP7002444B2 (ja) 2016-03-28 2022-01-20 武田薬品工業株式会社 医薬
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
CA3051699A1 (en) 2017-02-08 2018-08-16 Ovid Therapeutics Inc. Methods of treating seizure disorders and prader-willi syndrome
AU2018265353A1 (en) 2017-05-09 2019-11-21 Zogenix International Limited Methods of treating Doose syndrome using fenfluramine
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190125697A1 (en) 2017-09-26 2019-05-02 Zogenix International Limited Method of reduction in convulsive seizure frequency
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
EP3781671A4 (en) 2018-04-18 2022-01-26 The Trustees of Columbia University in the City of New York GENE THERAPY FOR DISEASES CAUSED BY IMPACTED NUCLEOTIDE POOLS, INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3820459A1 (en) 2018-07-10 2021-05-19 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
EP3829558B1 (en) 2018-07-27 2024-07-03 Xenon Pharmaceuticals Inc. Method for treating epilepsy
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
EP3887481A4 (en) 2018-11-30 2022-08-03 Zogenix International Limited METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
EP3930841A4 (en) 2019-02-25 2022-11-30 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
EP4395753A4 (en) 2021-09-01 2025-05-07 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Also Published As

Publication number Publication date
IL290727A (en) 2022-04-01
US11040018B2 (en) 2021-06-22
CN120241681A (zh) 2025-07-04
ES3029536T3 (en) 2025-06-24
US11786487B2 (en) 2023-10-17
RU2019105059A (ru) 2020-09-25
CA3032996A1 (en) 2018-03-01
TWI776407B (zh) 2022-09-01
TW202131908A (zh) 2021-09-01
RU2019105059A3 (es) 2020-11-25
EP3518975B1 (en) 2025-04-09
JP2024180450A (ja) 2024-12-26
AU2021204250B2 (en) 2022-09-01
EP3518975A1 (en) 2019-08-07
US20210393550A1 (en) 2021-12-23
US10603290B2 (en) 2020-03-31
NZ750691A (en) 2021-06-25
JP2022180461A (ja) 2022-12-06
RU2021106383A (ru) 2021-04-05
US20180055789A1 (en) 2018-03-01
AU2021204250A1 (en) 2021-07-22
WO2018037306A1 (en) 2018-03-01
US11406606B2 (en) 2022-08-09
CA3032996C (en) 2025-05-06
KR20250040753A (ko) 2025-03-24
EP4201427A1 (en) 2023-06-28
US11759440B2 (en) 2023-09-19
TW202432093A (zh) 2024-08-16
US20200246281A1 (en) 2020-08-06
TW202308601A (zh) 2023-03-01
US20210267916A1 (en) 2021-09-02
KR20190040237A (ko) 2019-04-17
AU2017315273A1 (en) 2019-03-07
IL264637B (en) 2022-04-01
KR20230021172A (ko) 2023-02-13
MX2019001799A (es) 2019-06-13
IL290727B2 (en) 2023-12-01
US20220125743A1 (en) 2022-04-28
AU2022279469A1 (en) 2023-02-02
RU2746000C2 (ru) 2021-04-05
IL290727B1 (en) 2023-08-01
US20190083424A1 (en) 2019-03-21
AU2022279469B2 (en) 2024-05-02
JP2019526544A (ja) 2019-09-19
CN109689103A (zh) 2019-04-26
SG11201900975XA (en) 2019-03-28
AU2017315273B2 (en) 2021-04-29
TW201821071A (zh) 2018-06-16
ZA201900766B (en) 2020-10-28
TWI722233B (zh) 2021-03-21

Similar Documents

Publication Publication Date Title
MX2023005140A (es) Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
ZA201807256B (en) Inhibitors of activin receptor-like kinase
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2017001512A (es) Compuestos activos hacia bromodominios.
SG10201805024YA (en) Methods useful in the synthesis of halichondrin b analogs
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
PH12018500627A1 (en) Compounds and compositions for the treatment of ocular disorders
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
MX390051B (es) Antagonistas de ep4.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CL2016000397A1 (es) Tratamiento contra el cáncer
MX379371B (es) Composiciones.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12016502527A1 (en) Stabilized desmopressin
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MX2018002449A (es) Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas.
IN2013MU03034A (es)
UA92247U (ru) ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
IN2013CH02437A (es)